Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Preoperative PET may lower unnecessary lung cancer surgeries

Presurgical scanning for metastatic non-small cell lung cancer appears to lower incidence of unnecessary surgeries, according to an analysis published Jan. 21 in the Journal of Nuclear Medicine.

Thumbnail

High estrogen and diabetes a recipe for dementia in women

The combination of higher estrogen levels and a diabetes diagnosis is associated with 14 times the risk of developing dementia for older women, according to a study published Jan. 29 in Neurology.

Eli Lilly announces 2% revenue decline in fourth quarter

The makers of F-18 florbetapir, also known as Amyvid, declared an 2 percent drop in global revenues in the final quarter of 2013 to just over $5.8 billion, though revenues for the full year reflected a 2 percent increase to slightly more than $23.1 billion.

Blood pesticide levels linked to Alzheimer’s

Higher serum levels of pesticides could be contributing to a higher risk of developing Alzheimer’s disease, according to a study published online Jan. 27 in JAMA Neurology.

BiOS biomedical optics symposium convenes in San Francisco

The largest biomedical optics conference in the world is set to meet Feb. 1-6 at Moscone Center in San Francisco as part of the larger Photonics West exposition, presenting a total of 4,600 papers, 93 conferences, 17 plenary sessions and two technical exhibitions.

Medical sensor market expected to reach $15.5B in five years

The industry for medical sensors, which includes diagnostic imaging and disease monitoring, was valued at $10.1 billion in 2012 and is expected to grow significantly by 2019, according to an industry sector report published Dec. 5 by Transparency Market Research.

Thumbnail

Value of amyloid imaging is ‘uncertain’

A sweep of more than 550 articles from the medical literature on Alzheimer’s disease diagnosis left reviewers questioning the utility of a positive beta-amyloid scan, according to a meta-analysis published in the January issue of JAMA Internal Medicine. 

Discerning infection from inflammation: A new PET/CT technique

Antimicrobial peptide PET/CT imaging with gallium-68 appears to break through previous roadblocks in differentiating infections and sterile inflammatory processes, according to a study published Jan. 16 in the Journal of Nuclear Medicine.